Sobi, Inc is conducting a phase III, multicenter, open-label clinical trial in Japan to evaluate avatrombopag, a thrombopoietin receptor agonist, in chronic adult ITP. Participants must be 18+ years old with chronic ITP (at least 12 months since diagnosis) with a platelet count <30x109/L and were unresponsive to previous ITP therapy. Participants with secondary ITP, inherited thrombocytopenia, are pregnant, or have a history of thrombosis, cardiovascular disease, liver disease, or cancer will be ineligible for this study. Individuals who have received IVIG/anti-D/corticosteroids/other thrombopoietin receptor agonists 1 week prior to the first platelet count or splenectomy/rituximab 12 weeks prior to the first platelet count will also be excluded from this study.
Japan
https://www.clinicaltrials.gov/ct2/show/NCT05369208?recrs=a&cond=Immune+Thrombocytopenia&draw=2
Recruiting
